Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Imipenem and aztreonam.

J D Sobel1

  • 1Division of Infectious Diseases, Wayne State University School of Medicine, Detroit, Michigan.

Infectious Disease Clinics of North America
|September 1, 1989
PubMed
Summary
This summary is machine-generated.

Aztreonam offers a safe alternative for gram-negative infections in penicillin-allergic patients and serves as an aminoglycoside-sparing agent, especially in elderly patients with renal insufficiency.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Automated microscopy and pH test for diagnosis of vaginitis - the end of empiricism?

NPJ digital medicine·2023
Same author

Resistance to Fluconazole of Candida albicans in Vaginal Isolates: a 10-Year Study in a Clinical Referral Center.

Antimicrobial agents and chemotherapy·2023
Same author

Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Recurrent bacterial vaginosis, relapse or reinfection: the role of sexual transmission.

BJOG : an international journal of obstetrics and gynaecology·2020
Same author

Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure.

Current infectious disease reports·2019
Same author

Candida parapsilosis Vaginal Infection-a New Site of Azole Drug Resistance.

Current infectious disease reports·2018
Same journal

Prevention and Control of Clostridioides difficile Infection for the Infectious Diseases Clinician.

Infectious disease clinics of North America·2026
Same journal

Infection Control Strategies to Prevent Emergence and Transmission of Resistant Gram-Negative Bacteria.

Infectious disease clinics of North America·2026
Same journal

Preventing the Spread of Tuberculosis in Health Care Settings.

Infectious disease clinics of North America·2026
Same journal

Threats to Success: Principles of Infection Prevention and Control in Health Care Settings, Part 2: Device and Pathogen Management.

Infectious disease clinics of North America·2026
Same journal

Ventilator-Associated Events: Surveillance and Prevention.

Infectious disease clinics of North America·2026
Same journal

Nosocomial Fungal Infections: Epidemiology, Control Strategies, and Prevention of Candida and Other Yeasts.

Infectious disease clinics of North America·2026
See all related articles

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Clinical Medicine

Background:

  • Aztreonam use has been limited, with moderate enthusiasm for hospital formularies.
  • Its primary indication is for gram-negative bacillary infections in penicillin-allergic patients.
  • It is considered an alternative to extended-spectrum penicillins or third-generation cephalosporins.

Purpose of the Study:

  • To evaluate the clinical utility and safety of aztreonam.
  • To explore its role as an aminoglycoside-sparing agent.
  • To assess its efficacy in specific patient populations and in combination therapy.

Main Methods:

  • Clinical efficacy comparison with aminoglycosides.
  • Evaluation of therapeutic index, focusing on nephrotoxicity and ototoxicity.

Related Experiment Videos

  • Assessment of use in elderly patients and those with renal insufficiency.
  • Analysis of combination therapy with non-beta-lactam agents.

    • Main Results:

    • Aztreonam demonstrates clinical efficacy similar to aminoglycosides.
    • It offers a higher therapeutic index due to lack of nephrotoxicity and ototoxicity.
    • It is an effective and safe alternative to aminoglycosides, particularly in elderly patients with renal insufficiency.
    • Aztreonam can be used effectively in combination with non-beta-lactam agents for mixed infections.

    Conclusions:

    • Aztreonam is a valuable therapeutic option for gram-negative infections, especially in penicillin-allergic individuals.
    • Its favorable safety profile makes it a suitable aminoglycoside-sparing agent, particularly in vulnerable patient groups.
    • Further research may explore its synergistic potential with other antibiotics.